Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Peginterferon alfa-2a, ATC L03AB11 für die Zeit 01.08.2026 - 31.07.2028

Section 130a, paragraph 8, SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, relating to the above-mentioned substance Peginterferon alfa-2a, ATC L03AB11, the DAK-Gesundheit intends to conclude discount contracts for medicines with as many interested pharmaceutical companies as possible until new medicines discount contracts come into force. A discount contract under the approval model for the above-mentioned substance comes into force for the first time on 01.08.2026 and ends on 31.07.2028. It ends automatically with the entry into force of the exclusive contract, regardless.